| Business Summary | | Alliance
Pharmaceutical
Corp.
is
a
pharmaceutical
research
and
development
company
that
focuses
on
developing
scientific
discoveries
into
medical
products
and
licensing
these
products
to
multinational
pharmaceutical
companies
in
exchange
for
fixed
payments
and
royalty
or
profit
sharing
payments.
To
date,
the
Company
has
developed
three
products
through
initial
clinical
(human)
trials
and
is
in,
or
has
completed,
pivotal
clinical
trials
for
these
products.
The
products
are
Oxygent,
an
intravascular
oxygen
carrier
to
temporarily
augment
oxygen
delivery
in
surgical
and
other
patients
at
risk
of
acute
tissue
hypoxia
(oxygen
deficiency);
Liquivent,
an
intrapulmonary
agent
for
use
in
reducing
a
patient's
exposure
to
the
harmful
effects
of
conventional
mechanical
ventilation;
and
Imavist
(formerly
named
Imagent),
an
intravenous
contrast
agent
for
enhancement
of
ultrasound
images
to
assess
cardiac
function
and
organ
lesions
and
to
detect
blood
flow
abnormalities. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Alliance
Pharmaceutical
is
a
pharmaceutical
research
and
development
company
focused
on
developing
scientific
discoveries
into
potential
medical
products.
For
the
nine
months
ended
3/31/01,
revenues
decreased
90%
to
$1.6
million.
Net
loss
increased
34%
to
$46.9
million.
Revenues
reflect
the
absence
of
sales
of
the
PulmoSpheres
technology
to
Inhale
Therapeutic
Systems.
Higher
loss
reflects
payments
to
outside
researchers
for
clinical
trials. | More
from
Market Guide: Significant
Developments |
| | | | FY2000 Pay | |
| Duane Roth, 50 CEO
and Chairman | $513K | Theodore Roth, 49 Pres
and COO | 361K | Harold DeLong, 52 Exec.
VP, Bus. Devel. | 257K | Artemios Vassos, M.D., 53 Exec.
VP and CSO | 401K | David Klein, Ph.D., 67 Sr.
VP, Pharmaceutical Devel. | -- | Dollar amounts are as of 30-June-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|